171 related articles for article (PubMed ID: 37318861)
1. Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study.
Hong Z; Xu J; Chen Z; Xu H; Huang Z; Weng K; Cai J; Ke S; Chen S; Xie J; Duan H; Kang M
Int J Surg; 2023 Aug; 109(8):2168-2178. PubMed ID: 37318861
[TBL] [Abstract][Full Text] [Related]
2. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
Front Immunol; 2022; 13():836338. PubMed ID: 35300335
[TBL] [Abstract][Full Text] [Related]
3. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
4. Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal cancer: a propensity score matching.
Hong ZN; Zhang Z; Chen Z; Weng K; Peng K; Lin J; Kang M
Esophagus; 2022 Apr; 19(2):224-232. PubMed ID: 34988773
[TBL] [Abstract][Full Text] [Related]
5. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
Front Immunol; 2022; 13():970534. PubMed ID: 36275724
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Xu J; Cai Y; Hong Z; Duan H; Ke S
Int J Surg; 2024 Jan; 110(1):490-506. PubMed ID: 37800587
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
9. A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.
Wang K; Liang Y; Huang J; Xie X; Wu D; Chen B; Wang K; Shen Z; Li Y; Wang W; Hu X; Wang M
J Surg Oncol; 2023 Aug; 128(2):207-217. PubMed ID: 37036218
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.
Zhao J; Hao S; Tian J; Li Y; Han D
J Inflamm Res; 2023; 16():3351-3363. PubMed ID: 37576156
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis.
Zhao J; Hao S; Li Y; Liu X; Liu Z; Zheng C; Han D
Immunotargets Ther; 2023; 12():113-133. PubMed ID: 38026088
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study.
Hong ZN; Weng K; Peng K; Chen Z; Lin J; Kang M
Front Oncol; 2021; 11():797426. PubMed ID: 34970498
[TBL] [Abstract][Full Text] [Related]
13. Impact of perioperative decreased serum albumin level on anastomotic leakage in esophageal squamous cell carcinoma patients treated with neoadjuvant chemotherapy followed by minimally invasive esophagectomy.
Wang YJ; Xie XF; He YQ; Bao T; He XD; Li KK; Guo W
BMC Cancer; 2023 Dec; 23(1):1212. PubMed ID: 38066484
[TBL] [Abstract][Full Text] [Related]
14. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
15. Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.
Zhang H; Zhang Z; Yang L; Wu B; Chen Y; He H; Li C; Lin W; Lin J
J Thorac Dis; 2023 Mar; 15(3):1279-1288. PubMed ID: 37065590
[TBL] [Abstract][Full Text] [Related]
16. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study.
Xie SH; Yang LT; Zhang H; Tang ZL; Lin ZW; Chen Y; Hong ZN; Xu RY; Lin WL; Kang MQ
Front Immunol; 2024; 15():1332492. PubMed ID: 38375480
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1).
Zhang Z; Hong ZN; Xie S; Lin W; Lin Y; Zhu J; Yang X; Lin Z; Lin J; Kang M
Ann Transl Med; 2021 Nov; 9(21):1623. PubMed ID: 34926667
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma].
Chen R; Fu JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Apr; 26(4):312-318. PubMed ID: 37072306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]